Feasibilitystudy of leprosy active case findings by contact tracing and the administration of a single dose of rifampicin as post-exposure prophylaxis in Senegal
- Conditions
- A30Leprosy [Hansen disease]
- Registration Number
- DRKS00023299
- Lead Sponsor
- Deutsche Lepra und Tuberkulosehilfe e.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 14000
Anyone usually residing in the villages reporting leprosy cases in the last five years and are considered for active screening and aged 2 years or over regardless of their sex, social, ethnic or religious affiliation.
- Refusal to give informed consent for screening or for the disclosure of the diagnosis to other members of his family
- Refusal to give informed consent for PEP
- Age <2 years
- New leprosy confirmed (cases should be put on MDT if they have not yet received MDT) or suspected, until the disease is ruled out
- overt signs and / or symptoms of tuberculosis (patients with any of the following symptoms should be referred to a tuberculosis diagnostic center for screening for the following symptoms: cough for more than two weeks, night sweats, unexplained fever , weightloss)
- Treatment with rifampicin for a given reason within the last two years (e.g. for treatment of tuberculosis or leprosy, or as contact with another index case)
- Pregnancy (PEP can be given after childbirth)
- History of liver problems (eg jaundice) or kidney problems
- Allergy to rifampicin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method newly diagnosed patients during active case finding activity and in the following two years
- Secondary Outcome Measures
Name Time Method Grade 2 disabilities